Fabry patients express anger to Genzyme; Welch considering Senate run;

@FierceBiotech: Be the first to meet the 2011 Fierce 15. News | Follow @FierceBiotech

@JohnCFierce: Texas Gov. Rick Perry gets a stem cell treatment, then lobbies for the procedure. Article | Follow @JohnCFierce

> Fabry disease patients are up in arms again following Genzyme's announcement that Fabrazyme will remain unavailable this month. Column

> Biotech entrepreneur Steve Welch is considering a run for U.S. Senate in 2012 and appears more serious now than when GOPers first approached him earlier this year. Story

> Covance CEO Joe Herring finds a lot of drug companies knocking on his door these days offering deals. Story

> Hazardous waste penalties of $250,000 have stung Nathan Hamilton and Thomas Brennan, owners of the now defunct Metrigen, who allegedly scoffed at the $5,000 estimate for proper disposal and went with the $200 recycling bin option. Article

> PROLOR Biotech reported positive results from a Phase II trial of adults for its long-acting CTP-modified version of human growth hormone, indicating that a single weekly injection may replace seven consecutive daily injections of existing treatments. Release

And Finally... A 104-year-old 'super ager' can thank her lucky genes. Article

Pharma News

@FiercePharma: Surprise Provenge shortfall triggers Dendreon layoffs. Story | Follow @FiercePharma

> Gilenya isn't worth the price, NICE says. Story 

> Hong Kong widens GSK antibiotic recall again. News 

> Jimenez aims to keep off-patent Diovan in blockbuster territory. Article

> Chinese pricing plan threatens pharma profits. Item

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.